China Coronavirus Cases Up Sharply As Pharma Rushes To Aid
Kaletra Finding Off-Label Use
Executive Summary
AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.
You may also be interested in...
Boehringer Bets On External Innovation In Post-COVID China
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
Regulatory, Security Concerns Force Wuxi NextCODE To Cut China Ties
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
US Revocation Of Hong Kong Special Status To Rain On Biotech IPO Parade?
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
Need a specific report? 1000+ reports available
Buy Reports